Stockwinners Market Radar for March 31, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:16 EDT Cathie Wood's ARK Investment sold about 37.5K shares of Tesla today

20:14 EDT Cathie Wood's ARK Investment bought about 3.5M shares of UiPath today

18:24 EDT BlackBerry sees 'minimal' licensing revenue in FY23 - Sees cyber security revenue "broadly flat" year-over-year in FY23. Sees FY23 billings growth 8%-12%. Sees FY23 IoT revenue $200M-$210M. Comments taken from Q4 earnings conference call.

18:06 EDT Veris Residential appoints Chief Investment Officer and General Counsel - Veris Residential announced two executive appointments. Jeff Turkanis, former Head of U.S. Residential at Oxford Properties Group, has been appointed Chief Investment Officer, succeeding Ricardo Cardoso, effective April 4, and Taryn Fielder, former General Counsel at WashREIT, has been appointed General Counsel, succeeding Gary Wagner, effective April 18. Cardoso and Wagner will be leaving the company to pursue other opportunities following a transition period. In connection with the hiring of Fielder and Turkanis, and also in connection with the previous hiring of Amanda Lombard as Chief Accounting Officer, who will assume the role of CFO on April 1, Veris Residential also announed equity awards to be made to those three executives as a material inducement to their entering into employment with the company. The awards to Lombard and Fielder are each in the form of restricted stock units; Turkanis will receive a restricted stock unit award and a stock option award.

17:31 EDT Mayville Engineering CEO Robert Kamphuis to retire - Mayville Engineering announced that Robert Kamphuis has informed the company of his plan to retire from his current roles as chairman, president and CEO on September 30. Kamphuis joined MEC as president and CEO in 2005 and became chairman in 2007.

17:21 EDT Raytheon Technologies awarded $650.75M Navy contract - Raytheon was awarded a $650.75M fixed-price incentive contract for hardware production of the AN/SPY-6 Family of Radars and associated hardware. This contract includes options which, if exercised, would bring the cumulative value of this contract to $3.16B. Work is expected to be completed by November 2025. If all options are exercised, work will continue through June 2028. This contract was competitively procured via the beta.sam.gov website, with one offer received. The Naval Sea Systems Command is the contracting activity.

17:17 EDT Lockheed Martin awarded $3.27B Army contract - Lockheed Martin was awarded a $3.27B firm-fixed-price contract for full-rate production of AN/TPQ-53 radar systems and associated spare parts and services, and deployment to various Foreign Military Sales countries. Bids were solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of March 30, 2027. U.S. Army contracting Command is the contracting activity.

16:55 EDT Reata Pharmaceuticals completes rolling submission for omaveloxolone NDA - Reata Pharmaceuticals announced the completion of the rolling submission of a New Drug Application to the U.S. Food and Drug Administration for omaveloxolone for the treatment of patients with Friedreich's ataxia. This NDA is supported by the efficacy and safety data from the MOXIe Part 1, Part 2, and MOXIe Extension studies. The FDA has granted Fast Track Designation and Orphan Drug Designation to omaveloxolone for the treatment of Friedreich's ataxia. "This NDA submission marks an important step toward making a treatment available for patients with Friedreich's ataxia, a serious degenerative neuromuscular disorder with no approved therapies," said Warren Huff, Reata's Chief Executive Officer. "I want to thank all those who made this possible, especially our patients with Friedreich's ataxia, their families, and investigators, as well as our employees, for their tenacity and unwavering belief in the omaveloxolone clinical program. We look forward to the next steps on the path to making omaveloxolone available as a first-in-class therapy for Friedreich's ataxia, pending approval."

16:51 EDT Net 1 UEPS now expects Connect Group deal to close in April - Net 1 UEPS announced that further conditions to the transaction for the acquisition of 100% of the shares and claims in the Connect Group in South Africa have been fulfilled. Net1's confirmation that the facility agreements have become unconditional in accordance with their terms, is the final outstanding condition precedent to the transaction. Net1 intends to issue such confirmation upon finalization of the South African exchange control authorizations for relevant selling shareholders of the Connect Group. Following that, the parties will move to close the transaction. Net1 and the sellers of the Connect Group remain committed to closing the transaction, which is now expected to be in April.

16:41 EDT G1 Therapeutics announces results from trilaciclib study - G1 Therapeutics announced results of a retrospective, observational study describing the substantial burden of myelosuppression and its impact on healthcare resource utilization in 3,277 patients being treated with chemotherapy for extensive-stage small-cell lung cancer. The study also described patient outcomes from 21 patients receiving trilaciclib prior to chemotherapy; of these, 17 received commercial trilaciclib in the real-world setting, and four received trilaciclib in clinical trials. Results showed that the use of trilaciclib prior to chemotherapy was associated with a 50% reduction in the percent of patients with grade 3 myelosuppressive hematologic adverse events in at least one blood cell lineage and a 74% reduction in the percent of all-cause hospitalizations, compared to patients who received chemotherapy alone. The analyses were derived using structured, real-world, de-identified clinical patient level data from the Integra Connect oncology warehouse. Findings are being presented in a poster session at the Annual Conference of the National Comprehensive Cancer Network, held from March 31 to April 2. In the study, the researchers conducted a primary analysis of 3,277 patients who received chemotherapy alone and a secondary analysis from 21 patients who received trilaciclib prior to chemotherapy, including 17 who received commercial trilaciclib in the real-world setting. The researchers noted that future studies using data from larger patient populations are recommended to enable a more robust comparison between patients treated with trilaciclib prior to chemotherapy and patients treated with chemotherapy without trilaciclib.Utilizing data from the Integra Connect Database, the researchers quantified the prevalence and frequency of grade 3 myelosuppressive HAEs and associated healthcare resource utilization and all-cause hospitalizations.

16:40 EDT Queen's Gambit Growth Capital completes business combination with Swvl - Queen's Gambit Growth Capital announced the completion of its business combination with Swvl, a global provider of tech-enabled mass transit solutions, following an extraordinary general meeting of Queen's Gambit's shareholders held on March 30. The combined company has changed its name to Swvl Holdings Corp. The Class A ordinary shares and warrants of the combined company will continue to trade on NASDAQ under the ticker symbols "GMBT" and "GMBTW", respectively, through today. On April 1, Swvl Holdings Corp's Class A ordinary shares and warrants are expected to commence trading on NASDAQ under the ticker symbols "SWVL" and "SWVLW", respectively. Swvl received gross proceeds from the transaction of approximately $164.8M from its upsized, fully committed $111.5M PIPE and the receipt of approximately $53.3M of cash from Queen's Gambit's trust account net of redemptions. In addition, after the closing of the business combination Swvl will have access to additional capital via an additional PIPE commitment of $10.0M, which it expects to close in Q2, and a $471.7M equity financing facility.

16:35 EDT Adamis Pharmaceuticals, USWM announce U.S. launch of Zimhi - USWM and Adamis Pharmaceuticals announced the U.S. launch and availability of Zimhi. Zimhi is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose as emergency therapy in settings where opioids may be present.

16:32 EDT Hayward chief supply chain officer Don Smith to retire - Hayward Holdings announced that Don Smith, Senior Vice President, Chief Supply Chain Officer, plans to retire from Hayward after more than 15 years with the company. He will remain with the company through the transition of his successor, who will be announced at a later date. "Don has been an integral part of the Hayward senior leadership team for over 15 years and has been a driving force in shaping Hayward into the company it is today," said Kevin Holleran, CEO of Hayward. "He has built a high-performance culture in our manufacturing, supply chain and distribution organizations around the world, which continues to meet challenges and deliver growth for the company. We thank Don for his years of leadership and wish him well as he moves into this next chapter of his life."

16:30 EDT Mercury Systems appoints Steve Ratner as chief human resources officer - Mercury Systems (MRCY) announced that Steve Ratner will join the company as senior vice president and chief human resources officer, effective May 2. Reporting to president and chief executive officer Mark Aslett, Ratner will be focused on building a team and supporting the business in its pursuit of growth and scale. Previously, he was vice president of Human Resources for Raytheon Missiles & Defense, a Raytheon Technologies (RTX) business segment with approximately $16B in annual revenues and over 30,000 employees worldwide.

16:25 EDT GameStop plans to implement stock split through dividend

16:23 EDT Core & Main to acquire Lock City Supply Inc - Core & Main has entered into a definitive agreement to acquire substantially all of the assets of Lock City Supply Inc., a full-service distributor of water and wastewater products, based in New York.

16:20 EDT Valmont secures $209M multi-year order with Siemens Gamesa - Valmont Industries (VMI) "announced that Valmont SM has entered into a supply agreement with Siemens Gamesa (GCTAF) Renewable Energy to provide components for the next generation of rotor houses for the offshore wind market. The order is the largest single order in Valmont SM's history. Valmont SM, a Valmont company, is a leading provider of wind turbine towers and direct-drive generator rotor houses. Valmont SM's expert craftsmanship and advanced production facility have been highly valued by SGRE. For over twenty years, Valmont SM has partnered with SGRE to support renewable energy projects. This latest agreement emphasizes the strength of the partnership and demonstrates the increased demand for renewable energy solutions globally."

16:18 EDT FDA notifies Spero of deficiencies in tebipenem NDA - The FDA has notified Spero that, as part of its ongoing review of Spero's New Drug Application, or NDA, for tebipenem HBr, it has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The FDA stated that the notification does not reflect a final decision on the information under review. Spero intends to work with the FDA to seek to resolve the deficiencies expeditiously. The FDA previously assigned a Prescription Drug User Fee Act, or PDUFA, goal action date of June 27, 2022, for completion of its review of the NDA, and initially targeted the midpoint of that review period to communicate proposed labeling and, if necessary, any post-marketing requirement and/or commitment requests to Spero. The company noted that there are three months remaining before the PDUFA goal action date. Spero also has a late cycle review meeting scheduled with the FDA and expects to provide an update on or before its next earnings call in May 2022. "We continue to have an active dialogue with the FDA," said Ankit Mahadevia, M.D., CEO of Spero. "We are focused on doing everything we can to address the deficiencies and, given how early in the review period the labeling discussions were originally scheduled, we believe there would be sufficient time to progress to labeling discussions within the existing PDUFA timeframe. However, we do not yet know the effect of this notification, if any, on our anticipated timelines or on the ultimate approval prospects of tebipenem HBr. We continue to prepare for an anticipated commercial launch of tebipenem HBr in the second half of 2022, as we work with the FDA. If approved by the FDA, we believe tebipenem HBr may offer healthcare providers, payers and patients an important oral antibiotic alternative to IV treatment for cUTI for patients with limited oral treatment options."

16:16 EDT Helix Energy announces multi-year contract with Shell - Helix Energy "announces it has entered into a new multi-year contract with Shell Offshore to provide Well Intervention services in the U.S. Gulf of Mexico. Commencing in March 2022, the three-year contract includes an anticipated 75 days utilization per year with the option to add additional utilization days. Under the contract Helix will provide either the Q4000 or Q5000 riser-based semi-submersible well intervention vessel, a 10k or 15k Intervention Riser System (IRS), remotely operated vehicles, project management and engineering services to cover operations from fully integrated well intervention to fully integrated plug and abandonment well services. The Q4000 and Q5000 well intervention vessels provide an optimal platform for a wide variety of tasks, including subsea well intervention, field and well decommissioning, installation and recovery of subsea equipment, well testing and emergency well containment."

16:11 EDT Site Centers CAO Vesy sells 35,000 common shares - In a regulatory filing, Site Centers CAO Christa Vesy disclosed the sale of 35,000 common shares of the company on March 29 at a price of $16.879 per share.

16:08 EDT Olin, Mitsui announce blue water joint venture - Olin (OLN) and Mitsui & Co. (MITSY) announced a global strategic alliance to better serve customers. The companies have agreed to a memorandum of understanding to establish a joint venture that brings together Mitsui's top-notch global logistics, deep supplier and customer relationships, and breadth of product portfolio with Olin's scale, North American export capability, and production flexibility across the electrochemical unit portfolio. The joint venture will be an independent global buyer, supplier, and marketer of ECU-based derivatives, initially focused on globally traded (blue water) caustic soda and ethylene dichloride with potential future expansion into other ECU derivatives and related products. By combining the complementary geographic and functional strengths of Olin and Mitsui, the joint venture will enable customers to benefit from greater security of supply, enhanced logistics reliability, increased access to global product liquidity, and network optimization to support the decarbonization agenda. The parties expect to commence the joint venture later this year, subject to agreement of definitive terms and applicable regulatory approvals.

16:07 EDT Olin, Mitsui announce blue water joint venture Mitsui & Co - Olin (OLN) and Mitsui & Co. (MITSY) announced a global strategic alliance to better serve customers. The companies have agreed to a memorandum of understanding to establish a joint venture that brings together Mitsui's top-notch global logistics, deep supplier and customer relationships, and breadth of product portfolio with Olin's scale, North American export capability, and production flexibility across the electrochemical unit portfolio. The joint venture will be an independent global buyer, supplier, and marketer of ECU-based derivatives, initially focused on globally traded (blue water) caustic soda and ethylene dichloride with potential future expansion into other ECU derivatives and related products. By combining the complementary geographic and functional strengths of Olin and Mitsui, the joint venture will enable customers to benefit from greater security of supply, enhanced logistics reliability, increased access to global product liquidity, and network optimization to support the decarbonization agenda. The parties expect to commence the joint venture later this year, subject to agreement of definitive terms and applicable regulatory approvals.

16:06 EDT Alta Equipment Group sees FY22 adjusted EBITDA $137M-$142M - The company introduced an adjusted EBITDA guidance range of between $137 million and $142 million, net of new equipment floorplan interest for the full year 2022, representing a 16% increase over the prior year at the midpoint.

16:04 EDT Wells Fargo to expand use of nCino operating system - nCino (NCNO) announced that Wells Fargo (WFC) will expand its use of the nCino Bank Operating System to accelerate digital transformation within its Consumer and Small Business Banking division. Previously, Wells Fargo selected nCino as the technological foundation to transform its commercial lending operations.

15:49 EDT Enbridge awarded right to pursue development of Alberta carbon dioxide hub - The Government of Alberta announced that Enbridge has been awarded the right to pursue development of a carbon dioxide, or CO2, sequestration hub west of Edmonton, Alberta. Enbridge is developing the Open Access Wabamun Carbon Hub to support near-term carbon capture projects being advanced by project partners Capital Power Corporation and Lehigh Cement, a division of Lehigh Hanson Materials Limited. The Hub and associated carbon capture projects being advanced by Capital Power and Lehigh Cement represent an opportunity to avoid nearly 4M tons of atmospheric CO2 emissions with phased in-service dates starting as early as 2025. Once built, the Hub will be among the largest integrated CCS projects in the world and can be scaled to meet the needs of other nearby industrial emitters. The Hub's carbon transportation and sequestration facilities will be co-developed and ultimately co-owned with local Indigenous partners, including the First Nations Capital Investment Partnership and the Lac Ste. Anne Metis Community.

14:11 EDT Flutter's FanDuel to launch online sportsbook and casino in Ontario - FanDuel Group, a subsidiary of Flutter Entertainment plc, announced plans to expand mobile and online gaming to Ontario beginning April 2022, subject to successful AGCO registration and execution of an operating agreement with iGaming Ontario. "The industry leader's expansion to Canada promises to deliver new, interactive, and immersive ways for fans to engage further with their favorite leagues and teams safely and responsibly. FanDuel's Canadian expansion comes after the Alcohol and Gaming Commission of Ontario announced it will launch its highly-anticipated regulated market for single-game sports betting, allowing authorized sportsbook operators to begin taking bets on April 4," the company stated.

13:50 EDT SunPower says capital plan includes sale of 2.5M Enphase Energy shares - SunPower (SPWR) sees investment firepower of over $1B through 2025. According to the company's Analyst Day slides, more than $1B investment capacity through 2025 is the result of target leverage at less than 2.5-times debt to adjusted EBITDA that is anticipated to create incremental debt capacity over beginning 2022 net debt levels; and "anticipated proceeds from CIS sale and from 2.5M shares [Enphase] ENPH."

13:38 EDT Macy's to invest $584M in new North Carolina fulfillment center - Macy's announced plans to open a new fulfillment center in China Grove, North Carolina in 2024 to meet the growing demands of its omnichannel business. The 1.4 million-square-foot facility, with automated direct-to-consumer fulfillment capacity, will employ nearly 2,800 workers when fully operational. Macy's, Inc. will invest approximately $584M in this project, the company said in a statement. "This state-of-the-art facility is a significant milestone for Macy's, Inc. as we invest in strengthening our omnichannel ecosystem. It will support growth of our business as a leading omnichannel retailer," said Dennis Mullahy, Macy's, Inc. chief supply chain officer. "We are delighted to become a member of the China Grove community and look forward to partnering with local and state officials to bring jobs and drive opportunity for local residents." When fully operational, the China Grove Fulfillment Center will account for nearly 30% of Macy's, Inc.'s digital supply chain capacity and serve customers nationwide.

13:01 EDT Apple says Business Essentials now available for small businesses in U.S. - Apple announced that Apple Business Essentials is now available to all small businesses in the US. The new service brings together device management, 24/7 Apple support, and iCloud storage into flexible subscription plans. Apple also unveiled new AppleCare+ for Business Essentials options that can be added to any plan. Additionally, a two-month free trial will be available to all customers, including those who have been using Apple Business Essentials in beta. "Apple has a deep and decades-long commitment to helping small businesses thrive. From dedicated business teams in our stores to the App Store Small Business Program, our goal is to help each company grow, compete, and succeed," said Susan Prescott, Apple's vice president of Enterprise and Education Marketing. "We look forward to bringing Apple Business Essentials to even more small businesses to simplify device management, storage, support, and repairs. Using this new service leads to invaluable time savings for customers - including those without dedicated IT staff - that they can invest back into their business." Apple Business Essentials is now available as a subscription for all small businesses in the US. Flexible plans can be customized to support each user and device in an organization with up to 2TB of secure storage in iCloud, starting at $2.99 per month after a two-month free trial. Plans that include AppleCare+ for Apple Business Essentials start at $9.99 per month.

13:00 EDT BioSig shifting from R&D to commercial launch, CEO tells The Fly

13:00 EDT BioSig seeing double-digit increases in elective procedure growth, CEO says

12:00 EDT Phreesia falls -9.8% - Phreesia is down -9.8%, or -$2.89 to $26.49.

12:00 EDT UiPath falls -24.4% - UiPath is down -24.4%, or -$7.10 to $21.94.

12:00 EDT Local Bounti rises 16.1% - Local Bounti is up 16.1%, or $1.23 to $8.84.

11:55 EDT First Solar up 2% after SunPower says in talks for residential panels

11:15 EDT Fox News Media signs Caitlyn Jenner to contributor role - FOX News Media has signed Caitlyn Jenner as a contributor. Jenner, a television personality, Olympic gold medalist, motivational speaker, entrepreneur, and former California gubernatorial candidate, will offer commentary and analysis across FOX News Channel programming and various FOX News Media platforms. Jenner's first appearance will be on tonight's Hannity at 9 PM/ET.

10:59 EDT Brii says new data show dose-dependent reduction in HBsAg in BRII-835 study - Brii Biosciences (BRIBF) announced earlier that the company presented new data from a Phase 2 randomized, double-blind, placebo-controlled trial of BRII-835, or VIR-2218, in Chinese patients with chronic hepatitis B virus, or HBV, infection, at the 31st Conference of Asian Pacific Association for the Study of the Liver, or APASL 2022, taking place virtually from March 30 to April 3 in Seoul, South Korea. The data demonstrate that BRII-835, an investigational small interfering ribonucleic acid that mediates RNA interference, results in dose-dependent reduction in hepatitis B surface antigen, or HBsAg, in Chinese patients with chronic HBV infection who received two doses of BRII-835. Similar HBsAg reductions were observed in both HBeAg- and HBeAg+ patients. In addition, BRII-835 was well-tolerated, with all treatment emergent adverse events reported as mild or moderate, and no clinically significant alanine transaminase elevations were observed, the company said. "As part of our goal to develop a functional cure for chronic HBV , we are pleased that the data from this trial continue to support the potential of siRNA as the backbone of combination treatment regimens that are being evaluated in several ongoing trials. We look forward to seeing more data later this year from these trials in which BRII-835 is being investigated in combination with other agents," said Li Yan, M.D., Ph.D., Chief Medical Officer at Brii Bio.

10:32 EDT Comcast agrees to purchase 250MW of solar electricity from Constellation - Comcast (CMCSA) announced an agreement to purchase 250 megawatts of solar electricity from Constellation (CEG) that will power approximately 12% of its U.S. operations and the vast majority of its Mid-Atlantic operations with clean, renewable energy. The agreement will support construction of the Blue Sky Solar Project, currently being developed by Scout Clean Energy in Illinois, creating local jobs and bringing additional clean electricity to the U.S. power grid, Comcast said. Comcast is committed to being carbon neutral by 2035 for Scope 1 and 2 emissions.

10:11 EDT Motive Capital Corp trading halted, volatility trading pause

10:00 EDT Hoegh LNG Partners falls -10.5% - Hoegh LNG Partners is down -10.5%, or -83c to $7.06.

10:00 EDT UiPath falls -22.2% - UiPath is down -22.2%, or -$6.45 to $22.59.

10:00 EDT Redwire rises 8.7% - Redwire is up 8.7%, or 69c to $8.65.

09:53 EDT Intergrated Media Technology Ltd trading resumes

09:47 EDT Phreesia falls -11.3% - Phreesia is down -11.3%, or -$3.33 to $26.05.

09:47 EDT PROG Holdings rises 7.2% - PROG Holdings is up 7.2%, or $1.98 to $29.68.

09:47 EDT Vector Group rises 9.2% - Vector Group is up 9.2%, or 97c to $11.57.

09:43 EDT DigitalBridge promotes Ben Jenkins to president - DigitalBridge Group announced that Ben Jenkins, CIO at DigitalBridge Investment Management, has been promoted to the role of President and CIO of DigitalBridge.

09:42 EDT First Internet Bank eliminates overdraft fees - First Internet Bank has announced that it is removing overdraft fees on personal and small business deposit accounts. This change has been made to deliver a better - and less costly - banking experience for account holders.

09:34 EDT Oxbridge Re Holdings trading halted, volatility trading pause

09:32 EDT SciSparc closes JV targeting discovery of potential drugs for cancers, diseases - SciSparc announced completion of the previously announced joint venture agreement to focus on the discovery and development of potential drugs for cancers and other life-threatening conditions, MitoCareX Bio Ltd., an Israeli corporation. MitoCareX Bio will focus on investigating mitochondrial carriers, transport proteins crucial for cell viability. Because of mitochondrial carriers' significant role in transporting necessary metabolites for cell functioning across the inner mitochondrial membranes, the Company believes various life-threatening conditions, such as cancers and rare mitochondrial diseases, might be treated by regulating the function of mitochondrial carriers. In humans, the mitochondrial carrier family consists of 53 members and is the largest solute transporter. Pursuant to the terms of the JV Agreement, at closing, SciSparc delivered an initial amount of $700 thousands. Based on pre-determined milestones, SciSparc will further invest up to $1 million, for up to 50.01 percent ownership, in MitoCareX Bio over the next two years subject to, and according to a number of milestones agreed upon in the JV Agreement. MitoCareX Bio's innovative research will partly build upon successful proof-of-concept experiments performed in the UK.

09:22 EDT Crown Electrokinetics announce highlights of Stub Period conference call - Crown Electrokinetics reported its financial results for the fiscal 2022 Stub Period in an earnings call. Mr. Doug Croxall, Crown's CEO and Mr. Joel Krutz, CFO, shared with the Company investors and industry analysts, the results of the Stub Period ending on December 31st, 2021, including updates to product development, vertically integrated manufacturing; customer announcements, first generation product delivery as well as expected timing for second generation product release. The highlights of this call included: Mr. Croxall delivered a detailed description of the product feature set and capabilities for both first and expected second generation Smart Window Inserts. First generation Smart Window Inserts are expected to be delivered in summer 2022. Initial installations are expected to be in office buildings located in Houston, Los Angeles, San Jose, Philadelphia, Washington DC, and Austin. First generation Smart Window Insert will be manufactured in the Company's Corvallis and Salem, Oregon facilities. Crown expects to become an active supplier meeting ESG products to US-based office buildings, retrofitting their legacy infrastructure and assets to be environmentally responsible and energy efficient. Mr. Joel Krutz, CFO, reported on the financials of the Company and announced a Letter of Credit facility of $10 million available for a period of 2 years, to be used if required for operational financing.

09:20 EDT EzFill signs fleet fueling agreement with Chef Nissen Catering - EzFill Holdings announced a new fleet agreement with Chef Nissen Catering, effective immediately. EzFill will provide regular mobile fuel delivery service for the company. Chef Nissen is an active participant in the Summer BreakSpot program, which provides free meals to kids and teens across Florida.

09:18 EDT CareCloud releases CareCloud Remote solution - CareCloud has released CareCloud Remote, a new digital health solution for home healthcare practice groups that streamlines referral management, improves staff assignment for home case management, and gives administrators and clinicians visibility and control over operational metrics.

09:16 EDT Galaxy Gaming restructures board compensation - "As we enter the 2022 calendar year, we look ahead in focusing the Company's business efforts beyond on the severe negative existential impacts of the pandemic. We also, through substantial efforts of our collective team, set the Saucier litigation and related refinancing in our rear-view mirror in the midst of the tough operating environment of our customers which, in some cases, included complete closures. Additionally, in response to the significant increase in the price of our stock in 2021, we have decided to restructure Board compensation beyond the 35% reduction in equity compensation we recently announced," stated Mark Lipparelli, Chair of the Galaxy Board. "We modified our methodology and targeted aggregate annual Board compensation for 2022 at the levels presented below, for all members, and intend to pay such compensation 60% in cash and 40% in stock. Cash compensation will be paid monthly in arrears and stock compensation will be paid quarterly in arrears, with the stock valued at the average daily closing price in the last month of the quarter. Ms. Kondra and Mr. Lipparelli will receive only the compensation presented below for their service as the Audit Committee Chair and Board Chair, respectively. "Using a share price of $4.45, the proposed Board compensation plan would result in 74,157 shares being issued to our five Directors in 2022. Based on the 23,718,968 shares outstanding on March 28, 2022, this represents projected dilution of approximately 3/10ths of one percent. We appreciate shareholders' interest in and support for Galaxy, and we look forward to the Company's future success together."

09:10 EDT CleanSpark to expand mining operations in Texas with 500 MW of renewable power - CleanSpark announced that it has signed an agreement with Houston-based Lancium to secure an initial 200 megawatts, MW, at Lancium's renewably-powered datacenters in West Texas, with an option to add 300 MW more in the future. It is expected that approximately 50 MW of the purchased capacity will be operational by December 31, 2022, while the remaining 150 MW will be fully operational during Spring 2023. After completely using this capacity with the latest generation of bitcoin mining machines, CleanSpark will add an estimated 16.0 EH/s to its current forecasted hashrate of 4.0 EH/s. "Lancium's facilities are best-in-class, scalable and, importantly, draw their power from renewable-rich West Texas, which made Lancium an ideal partner for us to co-locate our machines," said Zach Bradford, CEO of CleanSpark. "This move is in keeping with our strategy of focusing on infrastructure first. We continue to build more capacity at our own bitcoin mining facilities while we partner with colocation service providers. This hybrid approach helps us ensure that we always have rackspace ready to deploy new machines when they are delivered to us by the manufacturers. Such speed and optionality is critical as we scale our mining operations from megawatts to gigawatts in the coming years." As of February 28, CleanSpark has over 22,000 bitcoin mining machines in operation, with over 20,000 Bitmain S19 series rigs pending delivery and deployment in batches through October 2022.

09:09 EDT Philips announces additions to portfolio of cardiology solutions - Royal Philips announced new additions to its innovative integrated portfolio of cardiology solutions at the American College of Cardiology's Annual Scientific Session & Expo. Philips' cardiology portfolio offers solutions for coronary artery disease, structural heart disease, arrhythmia and heart failure. It integrates diagnostic and interventional imaging, treatment devices, and cardiac patient monitoring solutions at each point in the patient journey with the aim to improve clinical outcomes, patient and staff experiences, and care pathway effectiveness. Adding to the strength and depth of its cardiology portfolio, at ACC.22 Philips is launching two major innovations. Philips Ultrasound Workspace, an industry leading vendor-neutral echocardiography image analysis and reporting solution that can be accessed via the web, allows clinicians to create seamless diagnostic workflows from the ultrasound exam room to the reporting room and beyond. Philips also announced the global availability of a new Ambient Experience solution connecting to Philips Image Guided Therapy System - Azurion, which aims to reduce patient anxiety during interventional procedures. Ambient Experience with FlexVision display offers patients a calming multi-sensory experience while staff prepare them for their procedure.

09:08 EDT Privia Health appoints Cocozza to board of directors - Privia Health announced the addition of Nancy Cocozza to its Board of Directors, increasing its Board to ten members. Cocozza, a former senior vice president and Medicare business leader with Aetna, will also serve on the Board's Audit Committee.

09:07 EDT Confluent appoints Gunjan Aggarwal as Chief People Officer - Confluent announced the appointment of Gunjan Aggarwal as Chief People Officer. Gunjan joins Confluent from RingCentral, where she most recently served as Executive Vice President and the company's first CPO. As Confluent's Chief People Officer, Gunjan will lead the people and places function for the company including talent acquisition and development, organization effectiveness, rewards and recognition, people operations, culture and inclusion, real estate and workplace experience.

09:06 EDT Surrey Bancorp appoints Pedro Pequeno as president, William Johnson as CLO - The Board of Directors of Surrey Bancorp have announced the promotion of Pedro Pequeno II to President of the Company and the Bank and William Johnson to Senior Vice President and Chief Lending Officer of the Bank as part of its management succession plan. Edward Ashby III will remain CEO of the Bank and of the Company and will continue to serve as a director of both entities. Pequeno has been with the bank since it opened in 1996. As Senior Vice President and Chief Lending Officer, Pequeno managed the bank's loan and credit divisions. Pequeno's new responsibilities include oversight of loan operations, deposit operations, branch operations, digital banking, compliance, and lending. Johnson served as a member of the Board of Directors from 1996 to 2012, when he resigned as a member of the Board of Directors to lead the bank's expansion into Elkin and Wilkes County. Most recently, Johnson served as the Bank's Western Regional Executive. Johnson will oversee all lending activity.

09:05 EDT LPL Financial adds separately managed account strategies to MWP platform - LPL Financial announced that advisors can now access separately managed account strategies as an investment option within Model Wealth Portfolios. The addition to MWP, the firm's largest centrally managed platform, with over $83B in assets under management, creates a unified managed account where advisors are able to pair SMA strategies with their own models or models from other third-party money managers, combining ETFs, mutual funds, and SMA strategies in one client account.

09:03 EDT Chase enters multi-year extension with Amazon for Prime Rewards Visa credit card - Chase, the U.S. consumer and commercial banking business of JPMorgan (JPM), announced a multi-year extension of the co-branded Amazon (AMZN) Prime Rewards Visa (V) Signature credit card. The extension reinforces the more than two decades-long commitment between Chase and Amazon to provide cardmembers rewards, benefits and customer service. The Amazon Prime Rewards Visa Signature credit card offers rewards to Amazon customers that include five percent back on all Amazon.com and Whole Foods Market purchases, two percent back at restaurants, gas stations and drugstores, and one percent back on every other purchase, available exclusively for eligible Prime members. In addition, cardmembers can enjoy no foreign transaction fees when traveling abroad or for cross-border shopping, no cap and no expiration on earned rewards, and no annual credit card fee.

09:02 EDT GoPro launches HERO10 Black Creator Edition - GoPro is rolling out the red carpet for its HERO10 Black camera with a specialty Creator Edition, featuring Emmy Award-winning HyperSmooth 4.0 stabilization; crisp, cinematic 5.3K video; and enough battery to power all-day productions thanks to Volta, the new battery and camera control grip at its base. For under $600, the HERO10 Black Creator Edition combines four premium GoPro products into an all-in-one content capturing powerhouse.

08:54 EDT Smith-Midland Corp sees increased sales volumes in Q2, Q3 of 2022 - The company said, "A continuing dynamic macro environment including increases in labor and material costs are a reality for most companies today. The Company expects the first quarter 2022 to experience similar inflationary factors and customer approval delays experienced during fourth quarter 2021. Smith-Midland anticipates increased sales volumes in the second and third quarter 2022. Continued infrastructure initiatives across the United States are anticipated to yield positive results for our portfolio of patented, proprietary, and customized products. Smith-Midland continues to take a long-term approach to growth in the business. The Company's raw material inventories are stable, and Smith-Midland is working hard to attract and retain labor. Management continues to work on expanding the licensee network and extending the geographic reach of Smith-Midland's portfolio of proprietary and patented products. The Company is focused on managing the things within its control and remains focused on the long-term strategic growth initiatives to drive shareholder value. We are poised to capitalize on the favorable demand trends and market fundamentals across our market area. We anticipate that both private and public construction activity will accelerate in 2022 and result in increased bidding, selling, production, and rental demand in 2022 and beyond. The trends, combined with the additional federal funding from the recent Infrastructure and Jobs Act and additional state infrastructure spending, support growing construction activities and Smith-Midland has the ability and capacity to supply the product and services needed in our market."

08:50 EDT Meta Materials provides update on Special Series A Preferred Stock Dividend - Meta Materials provided an update on the special Series A Preferred Stock dividend in relationship to the oil and gas assets which is now planned as a spinout of these assets and operations in a company that will be owned by the Company's Series A preferred stockholders. On January 14, 2022, META provided an update on the Company's oil and gas assets and operations. With the completion of work on four wells in December 2021, the Company believes that META remains in compliance with all aspects of its lease obligations, including its obligations pertaining to the CDC with University Lands on the Orogrande project. The next steps in the spinout include, but are not limited to, formal transfer of the assets through a contribution of certain subsidiaries that own the oil and gas assets to OilCo Holdings, a newly formed wholly owned subsidiary of META, ensuring that the OilCo capital structure supports a spinout and, making any necessary filings with the SEC. META has been utilizing a team of asset managers who bring significant experience in oil and gas exploration. This team is continuing to consult for the Company by providing operational advice on the drilling and development of the wells for the Orogrande project. This team is able to continue providing key planning and operational assistance for the full development of the Orogrande project. Should the OilCo spinout be consummated, the team will be evaluated for commensurate employment packages subject to all necessary approvals. In order to complete the spinout, the Company must complete an audit of the oil and gas operations. The Company engaged an auditor on March 21, 2022 to conduct the audit. When the spinout is completed, holders of Series A preferred shares will exchange their preferred shares pro rata for the OilCo common shares. The necessary audit and legal work related to the asset consolidation and spinout is expected to be completed in the coming months.

08:48 EDT BioLargo files Annual Report on Form 10-K - BioLargo filed its Annual Report on Form 10-K with the SEC for the year ended December 31, 2021. Here, the company has provided highlights of its financial, commercial, and developmental advancements throughout the past year.b"The past year was pivotal for BioLargo," said the company's CEO, Dennis Calvert. "The credibility we have built as cleantech innovators, solution providers, and engineering project integrators has resulted in a steady increase in organic growth and enabled us to secure remarkable channel partners like Garratt-Callahan and Ikigai Marketing Works to promote accelerated growth. Our engineering division broke revenue records in both the third and fourth quarters of last year. And notably, our balance sheet continued to improve throughout 2021 while we continued to invest in the development and launch of our innovative technologies. We are also working with a number of new industry champions and distributors that are just getting started representing our products and services and look forward to sharing more information about their progress in the future. We expect to make a big splash in the immediate future with our Aqueous Electrostatic Concentrator PFAS treatment system, including with new channel partnerships, and we soon expect to secure our first commercial accounts with our Advanced Oxidation System energy-efficient water treatment technology." Consolidated revenue for the year ended December 31, 2021, was $2,531,000, which was a 4% increase over 2020. Revenue in the fourth quarter of 2021 was $784,000, a 10% quarter-over-quarter increase, and a decrease of 14% as compared with the fourth quarter of 2020.

08:46 EDT Bridgeline Digital announces partnership with Optimizely adds another customer - Bridgeline Digital announced that their partnership with Optimizely continues to drive revenue with another customer within the B2B distribution sector. A leading wholesale distributor has purchased a $40,000 Hawksearch license from Bridgeline. This joint customer of Bridgeline and Optimizely will implement the recently released third-party site search integration on the Optimizely platform. The distributor will be using Hawksearch to power their eCommerce site for its ability to understand complex, industry-specific search queries, unit of measure conversion, navigation, and recommendations. CEO of Bridgeline, Ari Kahn says, "Optimizely was quick to distinguish Hawksearch as a leader in the B2B search space and decided to partner with us to offer the first out-of-the-box connector for the Commerce Cloud. We're so glad this is the first joint customer for our newest plugin and can't wait to see how they grow with our pre-integrated AI-powered search solution."

08:43 EDT Alico provides business update - Alico announces business activities that will continue to support its business strategy and generate greater returns for our shareholders. The current citrus harvest season has been a challenging one for Alico, as well as for the entire industry in Florida. In addition to a harvest season that was anticipated to produce less fruit than in the prior year, many of the state's citrus groves, including Alico's citrus groves, were impacted by a freeze event in late January 2022. Alico took precautionary measures to minimize the impact this weather event had on its groves and production. Alico currently estimates an 11% decrease in its annual box production this year, compared with the prior season. Pricing for citrus has increased for the second consecutive year and the Company expects its pricing will approach, and may even reach, the ceiling prices on its long-term supply contracts with Tropicana this season. The Company has entered into a Purchase Option Agreement with a third party, E.R. Jahna Industries for the sale of approximately 899 acres of land at a price of approximately $11,500 per acre. The acres subject to the Option Agreement, which are currently part of the Company's aggregate citrus grove acreage, consist of 340 net citrus acres, 130 acres of cane, 209 acres of pastureland and 220 support acres. This month, Alico exercised a right of first refusal to purchase approximately 85 undeveloped acres near the previously-owned Alico Plant World, which had been sold by Alico in 2017, for approximately $2.4 million. The Company owns approximately 90,000 acres of mineral rights, mostly comprised of oil and gas, sand and shell, but Alico has not been aggressively monetizing these rights. The Company is continuing with its citrus tree replanting program and as previously disclosed, has planted approximately 1.5 million trees since the beginning of fiscal year 2018 through the end of its fiscal year ended 2021.

08:40 EDT Horizon says UPLIZNA effective in patients with newly-presenting NMOSD - Horizon Therapeutics announced the presentation of a post-hoc analysis from the N-MOmentum Phase 3 pivotal trial of UPLIZNA, showing that the medicine was safe and effective in NMOSD patients who were treated with UPLIZNA after having only one attack. These data are being presented during a poster session at the American Academy of Neurology 2022 Annual Meeting in Seattle April 2-7 and virtually April 24-26. UPLIZNA is the first and only FDA-approved CD19+ B-cell-depleting monotherapy proven to reduce the risk of attacks in adults with NMOSD who are anti-aquaporin-4 antibody positive. This analysis aimed to clarify how prior history of attacks might affect the response to UPLIZNA by evaluating the medicine's effect among individuals with newly-presenting NMOSD who were enrolled in the 28-week randomized, placebo-controlled period of the trial after their first attack compared to individuals with a history of two or more attacks... In addition, an analysis from the N-MOmentum trial will be presented showing long-term treatment with UPLIZNA improved pain outcomes in patients with NMOSD. Pain is a common, debilitating symptom of NMOSD that can dramatically impact daily activities. Previously presented data demonstrated improvements in pain scores after treatment with UPLIZNA. The new analysis builds on those findings by showing a durable, long-term benefit in managing pain, with year-over-year improvements from baseline as measured by the 36-item short-form survey body pain subscore...UPLIZNA is indicated for the treatment of neuromyelitis optica spectrum disorder NMOSD in adult patients who are anti-aquaporin-4 antibody positive.

08:36 EDT MusclePharm to launch whey protein drink line in the summer - MusclePharm Corporation announced it will be expanding into the ready-to-drink protein category with the launch of its new whey protein drink line in the summer of 2022. The new high protein beverage line will be marketed under the leading MusclePharm brand and will contain over 20g of protein, be sugar free and will be available in multiple flavors.

08:34 EDT Rush Street Interactive receives RG Check iGaming Accreditation from RGC - Rush Street Interactive announced it has become the first U.S.-based online casino and sports betting company to receive RG Check iGaming Accreditation from the Responsible Gambling Council, or RGC, for its BetRivers.com and PlaySugarHouse.com sites.

08:33 EDT Intel to acquire Granulate Cloud Solutions, terms undisclosed - Intel announced an agreement to acquire Granulate Cloud Solutions, an Israel-based developer of real-time continuous optimization software. The acquisition of Granulate will help cloud and data center customers maximize compute workload performance and reduce infrastructure and cloud costs. Deal terms are not being disclosed.The transaction is expected to close in the second quarter of 2022, subject to typical closing conditions. At that time, Granulate's approximately 120 employees will be integrated into Intel's Datacenter and AI business unit.

08:32 EDT Informatica selected by Saudi Airlines to modernize its data strategy - Informatica announced that Saudi Airlines has selected Informatica to help modernize its data strategy and transform the customer experience to support the region's ambitious growth targets. Informatica's Intelligent Data Management Cloud will enable Saudi Airlines to reimagine how they manage and innovate with their data.

08:31 EDT CME Group to expand its suite of Micro E-mini S&P 500 options - CME Group announced it will expand its suite of Micro E-mini S&P 500 options with the launch of Tuesday and Thursday Weekly options on April 25, pending regulatory review. These new weekly options contracts will complement the existing Monday, Wednesday and Friday Weeklies, End-of-Month and Quarterly options on E-mini S&P 500 futures.

08:28 EDT NRx Pharmaceuticals' nebulized Zyesami did not show benefit in COVID-19 - NRx Pharmaceuticals announced in collaboration with Quantum Leap Healthcare Collaborative, or QLHC, that the nebulized form of Zyesami - Aviptadil -, in the I-SPY COVID Trial of Critical COVID-19 patients has been stopped. The I-SPY COVID Trial is a phase 2 trial designed to rapidly screen potential agents that could substantially improve treatment for severely and critically ill COVID-19 patients. QLHC is the sponsor of the I-SPY COVID TRIAL. The intravenous form of Zyesami is currently being tested in the ACTIV-3b Phase 3 trial, which continues enrolling. The nebulized form was selected for inclusion in the I-SPY COVID Trial to determine whether this simpler form of delivery via self-inhalation through a mouthpiece would be effective in speeding recovery from and/or preventing death from COVID-19-related ARDS. The data suggested there was a low probability that the addition of this dose of nebulized Aviptadil to backbone therapy via mouthpiece administration, would improve outcomes in this population. The findings in the current I-SPY study may be due to the difficulty of effectively delivering nebulized medications via mouthpiece to critically ill patients when they are on high flow oxygen or nebulized into the breathing circuit for mechanically ventilated patients.

08:27 EDT Goodbody Health products included on FSA Novel Foods register - Goodbody Health is pleased to announce that, following the UK Food Standard Agencies publication of the Novel Foods approved list for CBD, the Company's application has been approved by the FSA to the next stage of the Novel Foods submission, being the publication of the FSA CBD Products register. The status of 'Awaiting Evidence' means the FSA are now awaiting the final toxicology results and are satisfied with all the other evidence submitted. Once received, and if successful, the Company will progress to the final Validated status.

08:25 EDT Portage Biotech provides update on clinical-stage, development programs - Portage Biotech provided an update on its clinical development programs and announced its development goals for the remainder of 2022. Q2-Q4 2022 Development Focus: The Company remains focused on advancing its pipeline of novel immuno-oncology therapeutics designed to prevent and overcome cancer treatment resistance. Clinical trials were initiated in 2021 for both of Portage's lead invariant natural killer T cell, iNKT, agonist programs, PORT-2 and PORT-3. Preliminary Phase 1 data received to date suggests PORT-2 was well tolerated when administered as a monotherapy, with no related adverse events. This has enabled a plan to accelerate opening of the combination safety cohort with Keytruda, in parallel with the ongoing high dose monotherapy cohort. Portage has decided to expand the PORT-2 study beyond the UK to accelerate clinical studies while addressing COVID-19 headwinds. The Company has hired a global clinical research organization and is preparing for regulatory submissions in other countries. Preliminary safety data for repeat dosing of PORT-3, a nanoparticle co-formulation of PORT-2 and NY-ESO-1 immunogenic peptides developed for the treatment of NY-ESO-1 positive solid tumors, is also favorable. The Company expects to submit data to a scientific congress for PORT-3 later this year. New Collaborations with Academic Partners to Enhance Strategic Goals: As part of its broader research and development strategy, Portage is partnering with experts and companies that could bring additional expertise and insights to help advance the science and open new avenues for development. New collaborations include a partnership with Dr. Francis Mussai and Dr. Carmela De Santo at University of Birmingham on iNKTs. Portage is also initiating a second collaboration with Dr. Robert Negrin and his team at Stanford University to evaluate the use of PORT-2 with iNKT cell therapies in animals. Clinical Development Goals for the Remainder of 2022: Generate safety and efficacy data on all products currently in clinical trials - PORT-2: iNKT agonist to treat melanoma and non-small cell lung cancer; initial efficacy data anticipated by the end of 2022. PORT-3: iNKT agonist co formulated in a nanoparticle with NY-ESO-1 peptide vaccine in tumors that express NY-ESO-1; preliminary efficacy data in patients expected year end, going into 2023. PORT-1: intratumoral amphiphilic formulation, developed in collaboration with our affiliate Intensity, being evaluated as a monotherapy and in combination with Keytruda and Yervoy to treat multiple solid tumors; multiple readouts expected in 2H 2022. Prepare additional compounds to enter clinical studies - PORT-5: Systemically delivered STING agent developed in collaboration with our affiliate Stimunity, is progressing towards the clinic. Continue to explore collaboration opportunities for all of our assets and evaluate new opportunities to expand immuno-oncology product portfolio

08:22 EDT Bunker Hill announces equity issuance to Teck Resources - Bunker Hill Mining is pleased to announce it has reached an agreement with a subsidiary of Teck Resources Limited to satisfy the remaining purchase price for the Pend Oreille Mill, for which an executed Asset Sale and Purchase Agreement was announced on March 7, 2022, in an equity issuance of the Company. The APA contemplated a total purchase price to be paid to Teck of US$2,750,000 in cash, or US$3,000,000 in cash and shares. A non-refundable deposit of US$500,000 was previously paid towards the purchase price. Teck has agreed to a non-brokered equity issuance to satisfy the remaining portion of the purchase price. Teck will receive 10,416,667 Units of the Company priced at C$0.30. Each Unit consists of one common share of the Company and one Common Share purchase warrant. Each whole Warrant entitles the holder to acquire one Common Share at a price of C$0.37 per Common Share for a period of three years. The Units and securities underlying them will be subject to a customary four month and a day hold period in accordance with applicable Canadian securities laws and to a concurrent six month hold period in accordance with applicable U.S. securities laws. The Equity Issuance is subject to receipt of all necessary regulatory approvals and closing. The Company has also agreed to grant Teck an exclusive option to acquire 100% of the zinc and lead concentrate production from the Bunker Hill Mine for an initial term of 5 years after the mine has commenced production of concentrates, subject to annual renewal and mutual cancellation rights thereafter. The option will be exercisable at Teck's election until March 31, 2023, with commercial terms to be based on applicable annual benchmarks and other commercially reasonable legal terms as mutually agreed. The Equity Issuance is expected to close on or about April 15, 2022. Separately, the private placement of Special Warrants of up to C$15,000,000, as announced in the Company's news release dated March 9, 2022, is expected to close on or about April 1, 2022.

08:21 EDT VBL Therapeutics to host KOL seminar on ovarian cancer - VBL Therapeutics announced that it will host a key opinion leader luncheon and seminar on ovarian cancer on Monday, April 11, 2022 at 12pm Eastern Time at the St. Regis Hotel in New York, NY. The seminar will feature presentations and a panel discussion with KOL's Bradley J. Monk, MD, FACS, FACOG, of the University of Arizona College of Medicine and Creighton University School of Medicine, Richard Penson, MBBS, of Massachusetts General Hospital, and Kathleen Moore, MD, of OU College of Medicine, who will discuss the current treatment landscape and unmet medical need in treating patients with ovarian cancer. The live event will be hosted by Dror Harats, MD, chief executive officer of VBL Therapeutics. VBL's lead product candidate, ofra-vec, will be discussed as a potential treatment solution for platinum resistant ovarian cancer. Ofra-vec utilizes VBL's novel VTS platform and is being evaluated in VBL's registration enabling OVAL Phase 3 clinical trial. Ofra-vec's unique mechanism of action is designed to combine the blockade of tumor microvasculature with an anti-tumor immune response. OVAL is now fully enrolled with 409 patients globally, and topline data on the progression free survival primary endpoint are expected in the second half of 2022.

08:19 EDT Evolus enrolls first patient in extra strength Jeuveau trial - Evolus has enrolled its first patient in a clinical study evaluating an "extra-strength" dose for extended duration of Jeuveau, its flagship neurotoxin product and the first and only neurotoxin dedicated exclusively to aesthetics.

08:18 EDT Evolv awarded DHS Safety Act Designation for Evolv Express - Evolv Technology announced that Evolv Express , its artificial intelligence based weapons detection system, has been awarded the U.S. Department of Homeland Security SAFETY Act Designation as a Qualified Anti-Terrorism Technology . Technologies that are awarded the SAFETY Act Designation have undergone rigorous use and review to meet and/or exceed the DHS' performance standards that include examination of test results for weapons detection, operational use and effectiveness, manufacturing and quality assurance practices, and customer feedback. The Support Anti-Terrorism by Fostering Effective Technologies Act was introduced by Congress in 2002 to incentivize the creation of technologies to combat terrorism in the wake of 9/11. The SAFETY Act is intended to ensure that the threat of liability caused by a terrorist event does not deter manufacturers or sellers of effective anti-terrorism technologies from developing, commercializing and deploying technologies that could potentially save lives. The Acting Under Secretary for Science and Technology is the deciding official for current SAFETY Act applications. This Designation demonstrates Evolv's belief that the security industry demands a new standard for security screening that can adequately address threats to crowds where people gather without impacting their experience. The pinpointed accuracy of threats detected, insightful analytics that help improve security operations, and the continual improvements through machine learning are features that set Evolv apart from existing standards. Evolv Express is the only high-throughput weapons detection screening system to achieve SAFETY Act Designation.

08:16 EDT Cidara announces completion of dosing of healthy volunteers in Phase 1 trial - Cidara Therapeutics (CDTX) announced that the first cohort of healthy volunteers has been dosed in its Phase 1 trial of CD388, a highly potent long-acting antiviral immunotherapy designed to deliver universal prevention of seasonal and pandemic influenza. The study is being conducted under an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to develop and commercialize Cidara's Cloudbreak drug-Fc conjugates for the prevention and treatment of seasonal and pandemic influenza. The Phase 1 trial, which dosed its first healthy volunteer in mid-March, is a randomized, double-blind, dose-escalation study to determine the safety, tolerability and pharmacokinetics of intramuscular and subcutaneous administration of CD388 in healthy subjects. To date, dosing of the first, low-dose cohort has been completed and the next mid-dose cohort is advancing as planned. "Initiating the first human study of a long-acting DFC is a tremendous milestone for Cidara and our Cloudbreak platform. It is also a testament to our team's firm commitment to transforming universal viral protection for all," said Jeffrey Stein, Ph.D. president and chief executive officer of Cidara. "Based on its compelling profile, CD388 has the potential to address a critical unmet need for universal prevention and the treatment of seasonal and pandemic influenza, especially for those who remain insufficiently protected by current flu vaccines, such as patients with compromised immune systems or patients at high risk for severe complications. We are excited to continue advancing CD388 through the clinic with our collaborator, Janssen."

08:15 EDT Romeo Power completes phase one of move to new Orange County location - Romeo Power announced that it has completed the first phase of the company's move to its new state-of-the-art headquarters and manufacturing facility located in Cypress, California. The new facility includes 191,000 square feet of industrial space which is still under construction to build out critical laboratory and testing areas, as well as to prepare the manufacturing floor for operations. While construction is ongoing elsewhere in the building, employees in the sales, finance, accounting, and legal departments are now working from the office space. "A new era of Romeo Power's growth has begun," said Susan Brennan, Romeo's Chief Executive Officer. "Over the next several months, we will bring hundreds of jobs to Orange County. We look forward to being an active member of the Orange County business community from our new location in Cypress." Production is scheduled to commence in the Cypress factory later in 2022 with the transition from Vernon to Cypress expected to be completed during the third quarter of 2022. In the meantime, Romeo continues all development and manufacturing activities in its existing factory in Vernon, California.

08:15 EDT Philips launches Ultrasound Workspace at ACC 2022 - Royal Philips announced the launch of Ultrasound Workspace at the American College of Cardiology's Annual Scientific Session & Expo, ACC 2022. Philips Ultrasound Workspace is a vendor-neutral echocardiography image analysis and reporting solution that can be accessed remotely via a browser. By offering cardiologists a consistent set of on and off cart AI-driven image analysis and quantification tools, this next-generation echocardiography solution helps to improve productivity and consistency while also enhancing diagnostic quality. Access to archived legacy data, combined with off cart vendor neutral analysis capabilities, further enhances consistent quantification across all echo labs at all locations. "With its new remote, browser-based accessibility, Philips Ultrasound Workspace is the first advanced vendor-neutral 2D/3D echocardiography viewing, analysis, and reporting system that extends the superior user experience of Philips' cardiac ultrasound system EPIQ CVx into multiple connected environments," said Jeff Cohen, General Manager of Ultrasound at Philips. "We have combined the power of AI with deep clinical knowledge to create a solution that integrates into the workflows of healthcare providers to help drive efficient clinical decision-making. With Ultrasound Workspace, our customers can experience a whole new world of echocardiography workflow to help improve both the patient and staff experience."

08:13 EDT Sono Motors partners with Munchner Verkehrsgesellschaft for solar tech - Sono Motors is launching its proprietary solar technology to public transport for the first time in partnership with the Munchner Verkehrsgesellschaft. The novel solar bus trailer will hit the roads in the Munich metropolitan area in the near future, testing the energy yields as well as the potential of the technology in daily operation. Offering possible savings of up to 2,500 liters of diesel per year and an annual local CO2 saving potential of more than 6.5 metric tonnes per bus, Sono Solar Technology contributes to climate protection and the reduction of inner-city greenhouse gas emissions. 20 semi-flexible special photovoltaic modules provide over 2,000 watts of energy to power the vehicle's battery and electrical loads such as heating, ventilation, and air conditioning, as well as the trailer's steering system.

08:12 EDT Magnite's SpringServe announces strategic integration with FFalcon - SpringServe, now part of Magnite, announced a strategic integration with FFalcon to power the TCL Channel inventory. SpringServe's ad serving and inventory management technology helps clients streamline their monetization to capture the full value of their inventory while ensuring high quality ad experiences. Through this integration, SpringServe can power direct-sold and programmatic campaigns and the flexibility of its platform will allow FFalcon to help optimize and measure campaign performance. "SpringServe's platform is specifically designed to support video publishers and working with leading OEMs such as FFalcon is a natural next step as we continue to expand our global footprint," said Leon Siotis, Head of International, SpringServe. "This will bring more inventory options for content owners and video creators to power CTV campaigns in streaming environments. Our platform enables advertisers to better engage with audiences through a great end-user experience wherever they consume content."

08:11 EDT Grove launches brand awareness, advertising campaign for Upexi - Grove announces the initial launch of a billboard campaign in 3 major cities throughout the nation aimed at driving submission traffic and awareness for Upexi, the company's Amazon Brand Aggregator. The out of home advertising campaign will launch in early April in Boston, Dallas, and Los Angeles, aiming to garner over 40 million impressions across the next several months. Since the launch of Upexi, its wholly owned division to acquire promising Amazon and Ecommerce businesses, in October of 2021, Grove Inc's. daily submissions have been growing in volume. The number of candidates and the quality of many of the businesses has been encouraging for management to see, and validate the resources being expended to grow this vertical. The company's first acquisition of VitaMedica has seen substantial growth in Amazon FBA, and with new products in the pipeline for Vitamedica, the company remains confident in continued growth across the brand.

08:10 EDT Outlook Therapeutics submits BLA to US FDA for ONS-5010 - Outlook Therapeutics (OTLK) announced it has submitted its Biologics License Application, BLA, to the U.S. Food and Drug Administration, FDA, for ONS-5010, an investigational therapy which, if approved, will be branded as LYTENAVA, for the treatment of wet age-related macular degeneration. If approved, LYTENAVA could replace the current practice of using unapproved repackaged IV bevacizumab sourced from compounding pharmacies for the treatment of wet AMD. "This BLA submission for our investigational ONS-5010 not only marks a very significant moment for Outlook Therapeutics, but represents a real step forward for potentially providing an on-label, FDA-approved alternative for the most frequently used anti-VEGF treatment in wet AMD patients in the United States," said Russ Trenary, President and Chief Executive Officer, Outlook Therapeutics. "If approved for marketing, we hope to see our ophthalmic bevacizumab become a valuable on-label therapy offering clinicians and their patients a safe and effective ophthalmic formulation of a treatment whose value has been proven over many years of clinical practice. We are excited for the potential to offer an ophthalmic bevacizumab formulation that ships straight from our factory partners to distribution centers while avoiding the risks of using unapproved repackaged IV bevacizumab that is approved for intravenous use but not for intravitreal administration." In anticipation of potential FDA marketing approval in late 2022 or early 2023, Outlook Therapeutics has begun commercial launch planning, including partnerships with FUJIFILM (FUJIY) Diosynth Biotechnologies for drug substance, and with drug product manufacturer Aji Biopharma Services for finished drug product. The Company also is actively building out its distribution and commercial team structures.

08:09 EDT Xunlei announces $20M share buyback program - Xunlei announced that the Board of Directors of the Company has approved a plan under which the Company may repurchase up to $20 million of its shares over the next 12 months. The board will review the share repurchase program periodically and adjust its size and terms as necessary. Under the proposed plan, repurchases may be made from time to time on the open market at the prevailing market prices and via a trading algorithm, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. The shares to be repurchased can be both its ADSs and common shares. The repurchase plan will be funded from the Company's cash balance. As of December 31, 2021, the Company had cash, cash equivalent and short-term investments of approximately $239 million, and the balance of bank borrowings was about $20.2 million which is used to finance the construction of the Company's research and development and headquarters building.

08:08 EDT Axcelis announces follow on shipments of Purion Power Series implanters - Axcelis Technologies announced follow on shipments of the company's Purion XE high energy and Purion M medium current Power Series implanters to a leading power device chipmaker located in Japan. The systems will be used in high volume production of 300mm thin silicon wafer based MOSFET and IGBT devices for automotive and other power management applications.

08:07 EDT Galectin Therapeutics expects cash to fund operations through March 2023 - As of December 31, 2021, the Company had $39.6 million of cash and cash equivalents. The Company believes it has sufficient cash to fund currently planned operations and research and development activities through at least March 31, 2023.

08:07 EDT Papa John's in strategic refranchising deal aiding domestic development - Papa John's International announced that it has refranchised its majority stake in a joint venture between Papa Johns and Blue and Silver Ventures, . Sun Holdings, a leading multi-brand franchisee operator and one of Papa Johns largest domestic franchise partners, has assumed control of 90 Papa Johns restaurants in Texas. Blue and Silver Ventures continues to be a limited partner in the venture and their share of ownership remains unchanged. Financial terms of the transaction were not disclosed. The strategic refranchising deal between Papa Johns and Sun Holdings builds upon the historic development agreement signed by the two parties in September 2021, under which Sun Holdings will open 100 new restaurants across high-growth markets, including in Texas, by 2029, in addition to the restaurants it has acquired. Now with significant operational scale with the brand, Sun Holdings is strongly positioned to accelerate its development plans and Papa John's domestic growth. "Sun Holdings is a proven, well-capitalized operator who understands our ambitious goals to expand the footprint of our brand," said Amanda Clark, Papa John's Chief Development Officer. "We will continue to build new corporate restaurants as well as refranchise when we can provide our franchisees strategic scale to support the brand's long-term growth, with this deal as a great example." "We are excited to partner on an even larger scale with Papa Johns, an innovative brand that is well-positioned in the QSR industry and has already begun to deliver a high return on our investment," said Guillermo Perales, President and CEO of Sun Holdings. "We look forward to growing together and are thankful to the team at Papa Johns for the trust they are placing in Sun Holdings."

08:06 EDT Chipotle to test radio-frequency identification technology in Chicago area - Chipotle Mexican Grill announced it is testing radio-frequency identification technology to enhance its traceability and inventory systems at its Chicago distribution center and approximately 200 restaurants in the greater Chicago area. A leader in food safety, Chipotle is one of the first major restaurant companies to leverage RFID case labels to track ingredients from suppliers to restaurants via serialization.

08:04 EDT I-Mab announces voluntary lock-ups by key shareholders - I-Mab announced that the company's key shareholders including CBC Group and Hony Capital as well as its senior management team have voluntarily entered into a 180-days lock-up period commencing from March 31, and committed not to sell their shares in the company during the lock-up period. Actions are based on strong confidence in the company's globally competitive pipeline and rapid transformation towards a fully integrated biopharma company. The Key Shareholders and senior management may also consider extending the lock-up period subject to market conditions in the future. Concurrently with the voluntary Lock-up, solely for the purpose of satisfying customary contractual registration rights of the company's shareholders in certain shareholders agreement, the company will file a prospectus supplement with the SEC to register an aggregate number of 37,749,950 ordinary shares held by the Key Shareholders. With the voluntary Lock-up, the Key Shareholders declare no intention of disposing any of the company's shares by this registration.

07:57 EDT Science 37 appoints Shaalan Beg to Global Management Team - Science 37 Holdings nnounced it is adding Shaalan Beg, M.D., M.S.C.S. to its Global Management Team. Dr. Beg comes to Science 37 from the University of Texas, Southwestern Medical Center in Dallas, Texas where he served as Medical Director for the Clinical Research Office at the Simmons Comprehensive Cancer and held the position of Director Gastrointestinal Medical Oncology and Associate Professor of Hematology and Medical Oncology.

07:49 EDT Zenvia says Tencent accumulates 10.2% stake of its Class A common shares - Zenvia ( ZENV) announces to the market the acquisition by Tencent Holdings (TCEHY) of 10.2% of its Class A common shares in the market, according to an SEC filing on March 31. Tencent now indirectly owns 1,795,100 Class A common shares of Zenvia, representing a 10.2% Class A shares, or 4.3% of total common shares, and a 0.7% voting power, according to the filing.

07:46 EDT WisdomTree launches Solana, Cardano, Polkadot ETPs in Europe - WisdomTree has added three new physically-backed cryptocurrency ETPs to its crypto asset product range. On March 29, 2022, WisdomTree Solana, WisdomTree Cardano and WisdomTree Polkadot ETPs were listed on Borse Xetra and SIX, the Swiss Stock Exchange and today were listed on Euronext exchanges in Amsterdam and Paris. The ETPs have a total expense ratio of 0.95%, currently the lowest fees for ETPs providing access to these altcoins in Europe, and are passported for sale across the European Union.

07:41 EDT Agile Therapeutics announces first Twirla commercial - Agile Therapeutics announced the launch of its first consumer commercial intended to increase awareness of the Twirla weekly birth control patch. The new ad launched March 30, 2022 on connected TV, CTV, and will run during key months through the remainder of 2022. Deployment of the commercial is focused on Twirla's primary consumer target, 18- to 24-year-old women, and geotargeted in California, Florida, Illinois, New York and Texas, reaching 41%-45% of its primary consumer base in the country - equating to approximately 5.7M women.

07:39 EDT CloudMD announces cost optimization, operational integration activities - CloudMD Software & Services is pleased to provide an update on its cost optimization process, integration of its comprehensive health services platform and organizational structure. CloudMD's cost optimization team is dedicated to creating shareholder and client value through the integration of people, process, and technology across the entire organization. Since the start of the year, approximately $7.5 million of annualized run-rate costs have been eliminated from the organization through integration, cost-synergies and streamlining operational functions across the entire business. The full benefit of these cost savings is expected to be realized in the second quarter. This exceeds the expected $4 million in cost savings the Company previously disclosed. CloudMD has demonstrated its ability to execute on its cost optimization strategy to drive sustainable profitability by: Integrating MindBeacon's iCBT solution into CloudMD's Mental Health Support Solutions, providing user engagement through assessment and treatment options for mild, moderate and chronic conditions. Streamlining and consolidating key operational functions across Finance, IT, Human Resources, Marketing and Sales and leveraging industry leading talent to drive innovation, retention and capitalize on human capital. Strengthening Digital Health Solutions by creating a new product management team focused on innovation and continuing to meet the health needs of individuals. The Company believes there are additional efficiencies to be realized as it continues its integration efforts this year. In addition, CloudMD is also focused on cross-sell revenue synergies through its complete and connected health ecosystem, which will support continued strong top-line growth. As part of the cost optimization, CloudMD has made some changes to its organizational structure to streamline the operations and create a more efficient business. Several positions have been reorganized and / or consolidated to leverage important capabilities, share best practices and drive growth throughout the organization. As part of the reorganization, effective March 31, 2022, Kanchan Thindal has stepped down as the Company's Chief Operating Officer. Karen Adams, President, will assume the roles and responsibilities of COO for the Company. Through the organizational restructure, CloudMD has made several changes to consolidate and strengthen the depth of its leadership team including appointing Lu Barbuto, EVP Enterprise Health Solutions; Adam Kelly, Chief Commercial Officer; Aida Begovic, EVP Digital Health Solutions; John Plunkett, EVP Transformation and Strategic Planning; Jon Harju, SVP, Engineering; Bronwyn Ott, SVP, Human Resources and Olga McRae, Corporate Secretary. CloudMD has also introduced a process to continually review and evaluate its operational integration and additional changes may be implemented as indicated by such process. No changes have been made to CloudMD's current business units, Clinics & Pharmacies, Digital Health Solutions and Enterprise Health Solutions.

07:35 EDT Summit Materials converts to Portland Limestone Cement - Summit Materials announces that its Davenport plant, operated by Continental Cement Company, a subsidiary of Summit, has converted 100% of its annual production to Portland Limestone Cement . In 2021, the Davenport plant produced approximately 1.1M tons of cement. Portland Limestone Cement is a blended cement with a higher limestone content, which results in a product that has similar performance characteristics as traditional Portland Cement, but with a reduction in carbon footprint of 10% on average. "Continental Cement Company has been working with our customers and specifiers to commercialize Portland Limestone Cement in all of our markets, and we are delighted that PLC adoption has progressed quickly," commented David Loomes, Continental Cement President and Senior Vice President of Summit Materials. "PLC reduces concrete embodied carbon by approximately 10% while delivering resilient and durable infrastructure to our communities. The conversion of our Davenport plant can pave the way for more widespread adoption of PLC throughout our markets and more broadly throughout the United States."

07:35 EDT VersaBank signs agreement with first U.S. Point-of-Sale Finance partner - VersaBank has entered into an agreement with its first Point-of-Sale Finance partner in the U.S., a large, North American, commercial transportation financing business focused on independent owner/operators. As it does from time-to-time in its Canadian Point-of-Sale Finance business, VersaBank collaborated with Securcor Financial Group on origination and structuring of the transaction. The Bank expects to commence funding the partner in the coming weeks. VersaBank's Point-of-Sale Financing business operates via its Receivable Purchase Program, which purchases loan and lease receivables from finance companies across a variety of sectors.

07:34 EDT Studio City files annual report on Form 20-F - Studio City International Holdings announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2021. The annual report can be accessed under the Annual Reports section on the Company's investor relations website at https://ir.studiocity-macau.com/annual-reports.

07:33 EDT AeroClean expects to complete development, launch of Purgo Lift in 2022 - Commenting on the Company's outlook, Mr. DiBona stated, "With 2022 in full swing, we expect to remain acutely focused on growing our Prgo customer base by onboarding additional sales team members and developing sales channels through distribution networks and strategic partnerships supported by the continued ramp-up in manufacturing capabilities at our leading medical device contract manufacturer. While we have achieved improvements in manufacturing output since the commercial launch of Prgo in late Q3 2021, the ongoing global logistics and supply chain bottlenecks and shortages have increased lead times for electronics, semi-conductors, chips, and even recently-in-stock and short lead time items. The team has taken action to minimize the impact of these supply chain and logistics disruptions to ongoing production, and we expect these challenges will resolve towards the end of the first half of 2022. Further, we expect to complete the development and launch of Prgo Lift in 2022. We believe Prgo Lift is a break-through technology we expect will assist many companies' safe return to work where elevators remain an acute point of vulnerability. We are pleased to have completed our recent public offering as we are now well-positioned with sufficient operating liquidity to support the working capital requirements of growing Prgo inventories and sales and the completion of the Prgo Lift product launch. We are also pursuing inorganic growth opportunities and are in various stages of discussion with potential acquisition and/or merger targets. The Company has a solid balance sheet and public currency to pursue growth through synergistic, strategic acquisitions that contribute to our goal of becoming a leading provider of indoor air quality products and services. As our customers look for comprehensive indoor air quality solutions, our short and long-term growth strategy includes evaluating opportunities to expand our product and service portfolio with complementary, differentiated technologies while maintaining a strong level of liquidity," concluded Mr. DiBona.

07:32 EDT Sao Paulo State Military Police to deploy 7,000 additional Axon Body 3 cameras - Axon announced that Sao Paulo State Military Police will outfit an additional 7,000 officers with Axon Body 3 body-worn cameras backed by the digital evidence management solution Axon Evidence. PMESP will also become the largest agency in Latin America to deploy Axon's real-time situational awareness software, Axon Respond. In June 2021, PMESP became the first police agency in Brazil to equip 2,500 officers with Axon Body 3 cameras.

07:31 EDT Trevena receives up to $40M in OLINVYK ex-US royalty-based financing - Trevena announced that the Company entered into a royalty-based financing with an affiliate of R-Bridge Healthcare Fund. In connection with the R- Bridge Financing, Trevena will receive an upfront amount of $15 million, and $15 million upon first commercial sale of OLINVYK in China. The Company will also receive an additional $10 million upon achievement of either a commercial or financing milestone. The R-Bridge Financing will be repaid through assignment to R-Bridge of all royalties from the Company's license with its partner in China, Jiangsu Nhwa Pharmaceutical and through a 4% net revenue interest in the Company's US net sales of OLINVYK. This US revenue interest will be capped at $10 million if Chinese approval of OLINVYK occurs by year-end 2023. In the event Chinese approval does not occur by that time, the US revenue interest will increase to 7% and will continue until certain combined totals of US revenue interest and Chinese royalties are paid. The Company retains all milestones from its partnership with Nhwa, including a $3 million milestone on Chinese approval of OLINVYK. Trevena is not subject to financial covenants in connection with the R-Bridge Financing. Funding of the loan is subject to customary conditions, and is expected within 15 days. The Company provided to R-Bridge a negative pledge of all of its assets until Chinese approval of OLINVYK in connection with the R-Bridge Financing. Following such approval, the R-Bridge Financing will be non-recourse to Trevena, other than the Chinese royalty and capped US revenue interest.

07:29 EDT Kingsoft Cloud announces $100M share repurchase program - Kingsoft Cloud announced that its board of directors has authorized the Company to adopt a share repurchase program under which the Company may repurchase up to $100M of its ordinary shares in the form of American depositary shares during a twelve-month period.

07:27 EDT Delta 9 Cannabis closes acquisition of Uncle Sam's Cannabis assets - Delta 9 Cannabis (DLTNF) is pleased to announce that it has closed a transaction with Uncle Sam's Cannabis and Wissam El Annan to acquire all or substantially all of Uncle Sam's assets relating to the operation of seventeen retail cannabis stores in Alberta. The Company will also be closing it's previously announced $32 million in credit facilities from Connect First Credit Union Ltd. To provide additional funding, the Company will also complete a private placement of $10,000,000 in principal amount of senior secured second-lien convertible debentures by Sundial Growers Inc. (SNDL). The subscription price of $9,600,000 represents an original discount of 4%. The Sundial Debenture matures on March 30, 2025 and bears an interest rate of 10% per annum, subject to increase on the occurrence of certain events as set forth in the Sundial Debenture, payable monthly. Additional Details of Uncle Sam Transaction: The acquisition was completed through Delta 9 Cannabis Store, a wholly-owned subsidiary of the Company, pursuant to an asset purchase agreement between Delta 9 Cannabis Store, Uncle Sam and Wissam El Annan dated November 1, 2021, as amended by a first amending agreement dated December 20, 2021, a second amending agreement dated February 16, 2022 and a third amending agreement dated March 22, 2022. The seventeen Uncle Sam stores in Alberta operate under the Uncle Sam's Cannabis and Discounted Cannabis brands. The purchase price paid by Delta 9 Cannabis Store relating to the Uncle Sam Transaction was $12,500,000, subject to customary adjustments. $50,000 of the purchase price was satisfied by a cash deposit. The $12,450,000 balance of the purchase price was satisfied in cash on closing. Uncle Sam also received 6,666,667 common shares of the Company at a deemed price of $0.277 per Common Share, representing the 10-day volume weighted average price of the Common Shares on the Toronto Stock Exchange. The Uncle Sam's Cannabis retail cannabis stores have demonstrated significant revenue, EBITDA, and earnings growth over 2020 and 2021. The Company expects the Uncle Sam Transaction to be accretive in 2022 and 2023 before synergies. The acquisition represents an attractive revenue multiple of approximately 0.68x annualized revenue. The combination of the Uncle Sam cannabis stores and Delta 9's existing store network will make Delta 9 a leading retailer of cannabis products in Canada. The final closing of the Uncle Sam Transaction remains subject to the approval of the TSX. The Sundial Debenture is convertible by Sundial into at a conversion price of $0.35 per Common Share. If Delta 9 completes an offering of equity securities in the six months from the closing of the Offering at an issuance price that is equal to or less than $0.29 per Common Share, the Conversion Price will be adjusted downward to a share price that is equal to a 20.0% premium to the issuance price of such offering of equity securities provided that, until shareholder approval is obtained by Delta 9, such price is not less than the 5-day volume weighted average trading price of the Common Shares as of the date of the conversion of the Sundial Debenture. Delta 9 may, at its option, also convert 100% of the interest accrued and payable for the first quarter ending June 30, 2022 and 50% of the interest accrued and payable for the second quarter ending September 30, 2022 into Common Shares at a price equal to the 5-Day VWAP as to the date of interest payment. During an event of default that is ongoing, Sundial may, at its option, convert 100% of the interest accrued and payable into Common Shares at a price equal to the 5-Day VWAP as to the date of interest payment. In connection with the Offering, Delta 9 has undertaken to Sundial that it will seek, prior to June 30, 2022, the approval of the shareholders of Delta 9 for: the creation of Sundial as a control person of Delta 9; the issuance of a number of Common Shares greater than 25% of the current number of issued and outstanding Common Shares; the issuance of Common Shares in payment of interest on the Sundial Debenture at a 15% discount to the 5-Day VWAP of the Common Shares on the date of issuance; and the removal of the Floor Price for the conversion of the Sundial Debenture. The security in respect of the Sundial Debenture will be subordinated in all respects to the security. Delta 9 may redeem the Sundial Debenture, in whole or in part, prior to the Maturity Date, at a redemption price equal to par plus a make-whole amount and all accrued and unpaid interest. In connection with the Offering, Sundial and Delta 9 entered into a purchase agreement whereby Sundial was granted the right to participate in future debt or equity financings in accordance with Sundial's pro-rata as-converted ownership in Delta 9, subject to customary limits and exceptions.

07:24 EDT Alcanna completes plan of arrangement with Sundial Growers - Alcanna Inc. (LQSIF) announces the completion of the previously announced plan of arrangement with Sundial Growers Inc. (SNDL) under Section 192 of the Canada Business Corporations Act in accordance with the terms of the arrangement agreement between Alcanna and Sundial dated October 7, 2021, as amended by the amending agreement dated January 6, 2022. Pursuant to the Arrangement Agreement and the amended terms of the plan of arrangement attached thereto, Sundial acquired all of the issued and outstanding common shares in the capital of Alcanna from the holders of Alcanna Shares, for total consideration of approximately $320 million consisting of cash and common shares in the capital of Sundial. Pursuant to the Arrangement Agreement, each former Alcanna Shareholder is entitled to receive, in exchange for each Alcanna Share held: 8.85 Sundial Shares; and $1.50 in cash which was revised by the amending agreement on January 6, 2022 to include both Share Consideration and Cash Consideration. Following completion of the Arrangement, former Alcanna Shareholders will hold approximately 13.4% of the issued and outstanding Sundial Shares. The Alcanna Shares are expected to be delisted from the Toronto Stock Exchange at the close of business on April 1, 2022. It is expected that Alcanna will submit an application to cease to be a reporting issuer and to otherwise terminate its public company reporting requirements as soon as possible after delisting. The Arrangement Agreement is described in the management information circular and proxy statement of Alcanna dated November 9, 2021, and the material change report of Alcanna dated January 6, 2022, copies of which have been filed on SEDAR at www.sedar.com and are available on Alcanna's website at https://www.alcanna.com/ALCANNA-Special-Meeting-Materials. Following completion of the Arrangement, each Alcanna Shareholder ceased to be an Alcanna Shareholder and to have any rights in respect of their Alcanna Shares other than to receive the Revised Consideration payable to such former Alcanna Shareholder pursuant to the Plan of Arrangement.

07:19 EDT Parsons to highlight space domain capabilities at Space Symposium - Parsons Corporation will highlight capabilities critical to the world's evolving mission requirements at the 37th Space Symposium on April 4-7, 2022, in Colorado Springs, CO. The company has delivered capabilities in the space domain for decades, focusing on end-to-end solutions in command and control; small satellite development and launch; satellite ground operations; space domain awareness; assured position, navigation, and timing; and satellite resiliency mission areas. "We're transforming the space domain for our partners across the government and commercial industries," said Rich Aves, executive vice president and business development leader for Parsons' defense and intelligence business. "We provide end-to-end customized mission solutions that meet our customer's needs in the rapidly evolving space domain. With decades of experience supporting over 170 space missions, our capabilities enable operations for 50 percent of U.S. DoD satellites and 75 percent of NASA and NOAA satellites - we're proud of our history, but even more excited for our future."

07:18 EDT Orgenesis announces $14.8M private placement - Orgenesis announced that it has entered into a definitive securities purchase agreement with certain investors for the sale of 4,933,333 shares of the Company's common stock in a private placement at a purchase price of $3.00 per share and warrants to purchase up to 1,000,000 shares of common stock at an exercise price of $4.50 per share. The warrants are not exercisable until after six months and expire three years from the date of issuance. The Company expects to receive gross proceeds of approximately $14.8 million before deducting related offering expenses. The offering is expected to close on or about April 30, 2022, subject to customary closing conditions.

07:16 EDT Autolus receives EMA orphan medical product designation for obe-cel - Autolus Therapeutics announced that the European Medicines Agency has granted obe-cel, Autolus' leading CAR T clinical candidate, Orphan Medical Product Designation for treatment of acute lymphoblastic leukemia patients.

07:15 EDT ObsEva publishes 2021 annual report - ObsEva published its Annual Report 2021 to Shareholders.

07:14 EDT Rubicon Organics announces correction to Q4 2021 results date - Rubicon Organics is pleased to announce that it will be reporting its financial results for the year ended December 31, 2021 following the market close on Monday, April 18, 2022.

07:12 EDT OneWater Marine announces $50M share repurchase program - OneWater Marine announced that its Board of Directors approved a share repurchase program to repurchase up to $50M of the Company's Class A common stock from time to time in the open market, in privately negotiated transactions, or by such other means as will comply with applicable state and federal securities laws. This is the Company's first authorization for repurchases since its initial public offering.

07:11 EDT Trevena expects cash, cash equivalents to fund operations into Q4 of 2022 - The Company reported $66.9 million in cash and cash equivalents as of December 31, 2021, which it believes will be sufficient to fund operating expenses and capital expenditure requirements through the fourth quarter of 2022

07:09 EDT CynergisTek signs six-figure agreement with pediatric hospital - CynergisTek announced it has signed another six-figure agreement with one of the largest pediatric hospitals in the United States. CynergisTek will provide professional consulting and advisory services to this client in order to bolster the security of their networks and systems for operations and patient care.

07:08 EDT Amylyx falls 20% to $12.00 per share after resumption of trade - Shares of Amylyx are down about 20% after the stock resumed trading following its halt yesterday. Last night, Amylyx disclosed that the FDA AdCom voted 4-yes and 6-no on the efficacy of its AMX0035 in amyotrophic lateral sclerosis, or ALS.

07:06 EDT Eloxx Pharmaceuticals expects cash to fund operations into Q2 of 2023 - As of December 31, 2021, the company had cash and cash equivalents of $42.3 million, which combined with $7.0 million from the CF Foundation, Eloxx expects will be sufficient to fund its operations into the second quarter of 2023.

07:04 EDT PDS Biotechnology expects cash to fund operations through end of 2023 - The Company's cash balance as of December 31, 2021 was $65.2M. Based on the Company's available cash resources and cash flow projections, the Company believes this balance is sufficient to fund Company operations and research and development programs through the end of 2023.

07:03 EDT Oncolytics provides update on phase 1/2 GOBLET study - Oncolytics Biotech announced the successful completion of the three-patient safety run-in for the third-line metastatic colorectal cancer cohort of the phase 1/2 GOBLET study, following an independent review by the study's Data Safety Monitoring Board. The DSMB noted no safety concerns in these patients and has recommended that the study proceed to full enrollment pending clearance by the Paul Ehrlich Institute. The PEI recently cleared the study's pancreatic cancer cohort for full enrollment following a similar recommendation by the DSMB. The trial's anal cancer and first-line mCRC cohorts do not include safety run-ins and are proceeding as planned.

06:46 EDT KULR Technology secures battery safety contract with NASA - KULR Technology Group secured a battery safety contract with NASA to test its lithium-ion cells going into future battery packs designed for the Artemis Program, a series of United States-led international human spaceflight programs. The first launch of the program, the Artemis-I, is scheduled for May 2022. KULR performed the tests on cells in reserve for upcoming Artemis missions as well as other pending critical manned space voyages. The cells used on the missions are required to meet certification to NASA's specification for manned flight, EP-WI-037.

06:37 EDT Jaguar Health enters crofelemer agreement with Quadri Pharmaceuticals - Jaguar Health announced that the company has entered an agreement with Quadri Pharmaceuticals that grants Quadri Pharma exclusive promotional, commercialization, and distribution rights for specified human indications of crofelemer in Bahrain, Kuwait, Qatar, Saudi Arabia, the United Arab Emirates, or UAE, and Oman following regulatory approval to market crofelemer in these countries for the specified indications, including the indication currently approved in the U.S. for HIV-related diarrhea, and cancer therapy-related diarrhea, for which crofelemer is currently in a pivotal Phase 3 clinical trial. In addition, the agreement grants Quadri Pharma exclusive rights to distribute crofelemer in these countries in the immediate future under Named Patient Programs.

06:34 EDT Babcock & Wilcox selected for large biomass power plant in Louisiana - Babcock & Wilcox will partner as a preferred technology supplier with Kiewit Industrial to deliver Fidelis New Energy's planned net-negative carbon impact biomass power plant at the Port of Greater Baton Rouge, Louisiana. The 200 MW electric plant will be the largest of its kind in the world. The planned facility, called Project Cyclus, will provide power for Fidelis' state-of-the-art, 73,000-barrel-per-day Gron Fuels facility, which will produce sustainable aviation fuel, renewable diesel, green hydrogen, and bio-plastic feedstock with a net-negative carbon dioxide footprint. B&W will provide engineering, design, equipment, and technology services to support development of the biomass-fueled plant. The company's B&W Renewable business segment will design and supply a 200 MW electric, biomass-fueled bubbling fluidized bed boiler, while its B&W Environmental segment will provide its OxyBright oxy-combustion technology to isolate and capture CO2 for long-term sequestration, as well as a full suite of environmental technologies to control other emissions. The plant will utilize these technologies to produce clean energy with a net-negative carbon impact of over two million tons per year.

06:20 EDT Clovis jumps 35% to $2.24 after Phase 3 ATHENA-MONO trial meets endpoint

06:05 EDT Faraday Future provides update on status of filings delay and investigation - Faraday Future filed a Form 12b-25 notifying the SEC that it is unable to file its Annual Report on Form 10-K for 2021 within the prescribed time period, and does not expect to file it by the extended filing date pursuant to SEC Rule 12b-25, as a result of delays related to internal investigation work and remediation efforts. On February 1, the company filed a Current Report on Form 8-K disclosing that a special committee of independent directors of the company had completed an independent investigation into allegations of inaccurate company disclosures. Since then, the company continues to implement the appropriate remedial actions approved by the Special Committee and continues the additional investigative work and remedial work as recommended by the Special Committee. That work may result in further findings and remedial actions. The company needs additional time to complete the investigative work, implement remedial actions and finalize the company's financial statements and related disclosures for both the Q3 Form 10-Q and Form 10-K. The company currently expects to file the Q3 Form 10-Q and the Form 10-K on or prior to the May 6, 2022 Nasdaq deadline and expects to file its amended Registration Statement on Form S-1 promptly following the filing of the Form 10-K. The company received a notice of preservation and subpoena from the staff of the SEC stating that the SEC had commenced a formal investigation relating to the matters that were the subject of the Special Committee investigation. The company is cooperating fully with the SEC's investigation.

06:03 EDT Novavax submits request to expand CMA for Nuvaxovid in EU - Novavax announced submission of its request to expand the conditional marketing authorization, or CMA, of Nuvaxovid COVID-19 Vaccine in the European Union, or EU, to adolescents aged 12 through 17 years.

05:28 EDT Sasol Chemicals, Holiferm enter partnership to commercialize sophorolipids - Sasol Chemicals, a business unit of Sasol, and Holiferm announced a partnership to jointly develop new biosurfactants and enable the broad commercialization of sophorolipids. Sasol Chemicals has agreed to purchase the majority of sophorolipids produced at a new Holiferm manufacturing facility in the United Kingdom, which is under construction and scheduled to begin operations in early 2023. Sasol Chemicals will also fund Holiferm research and development to accelerate innovation initiatives to help meet growing demand for sustainable solutions in primary surfactants. Financial terms of the agreements between Sasol Chemicals and Holiferm were not disclosed.

05:24 EDT Mainz Biomed completes ColoAlert pre-submission process with FDA - Mainz Biomed announced that it has received supportive feedback from the FDA on the company's pre-submission package profiling the potential pivotal clinical trial design for ColoAlert, its detection test for colorectal cancer, or CRC. As Mainz prepares to launch ColoAlert's pivotal clinical trial, the company also announced the formal commencement of its reimbursement process for ColoAlert by scheduling an initial meeting with The Centers for Medicare and Medicaid Services, or CMS, in April. The CMS is a federal agency in the U.S. Department of Health and Human Services, or HHS, that administers the Medicare program and works in partnership with state governments to administer Medicaid, the Children's Health Insurance Program and health insurance portability standards.

05:17 EDT Baidu provides update on status under HFCAA - Baidu provided an update on its status under the Holding Foreign Companies Accountable Act, or HFCAA. Baidu is aware that the company has been identified by the SEC under the HFCAA on March 30. The company understands such identification may result from its filing of the annual report on Form 20-F for the fiscal year ended December 31, 2021. Baidu understands the SEC made such identification pursuant to the HFCAA and its implementation rules issued thereunder, and this indicates that the SEC determines that the company used an auditor whose working paper cannot be inspected or investigated completely by the PCAOB, to issue the audit opinion for its financial statements for the fiscal year ended December 31, 2021. In accordance with the HFCAA, a company will be delisted from a U.S. stock exchange only if the company has been identified by the SEC for three consecutive years due to PCAOB's inability to inspect auditor's working paper. Baidu has been actively exploring possible solutions. Baidu will continue to comply with applicable laws and regulations in both China and the United States, and strive to maintain its listing status on both Nasdaq and the HKEx.

05:12 EDT 36Kr Holdings acquires 7.27% equity interest in Hangzhou Jialin - 36Kr Holdings announced that it has acquired 7.27% equity interest in Hangzhou Jialin Information Technology, or Hangzhou Jialin, as one of the investors in its round B financing. The subscription price for Hangzhou Jialin is the same for the company and other independent investors in this financing round. The fair value of equity interest is RMB 40M. Hangzhou Jialin is a fresh produce supply chain solution provider in China. In connection with the transaction, the company has transferred its 100% equity interest in Beijing Dianqier, a subsidiary of the company which primarily provides interactive marketing dispense services, as consideration for the 7.273% equity interest in Hangzhou Jialin. The transactions were completed recently. The company expects to recognize approximately RMB 36M of gain from investment in the first quarter of 2022, which is subject to the auditor's further review.

05:07 EDT Pearson confirms Apollo no longer weighing offer after third proposal rejected - Pearson (PSO) notes yesterday's announcement from Apollo Group (APO) that it is no longer evaluating a possible cash offer for the company. The board of Pearson confirms that, on March 28, it received a third proposal from Apollo regarding a possible cash offer for the entire issued and to be issued share capital of the company at 870 pence per share. The third proposal followed two previous proposals from Apollo which were unanimously rejected by the board of Pearson. The board of Pearson considered the third proposal, together with its financial and legal advisers, and concluded that it "significantly undervalued the Company and its future prospects." Accordingly, the board unanimously rejected the third proposal. Pearson's board is "confident that the direct to consumer, lifelong learning strategy set out by Management in March 2021 will create sustainable, long-term value for Pearson stakeholders."